The company's stock moves higher on strong revenue growth and expanded margins, but the company sharply reduces guidance.
News & Analysis: Pernix Therapeutics Holdings
Pernix Therapeutics Holdings has secured pediatric approval for its migraine drug Treximet.
Pernix Therapeutics is giving up some of its big gains this past year in the wake of a deal to buy Zogenix's Zohydro ER drugs.
These five small-cap growth stocks could soar in 2015. Here's why.
Is this meaningful? Or just another movement?
Pernix, Myriad, Repros and OraSure were four big winners in the biotech space during the past two days. Here's the back story on these pharmaceutical stock pops.
Just the facts, Fool.